Neurodegenerative Diseases Market to Grow at 4.7% CAGR to 2019

May 14, 2015, 09:00 ET from ReportsnReports

DALLAS, May 14, 2015 /PRNewswire/ --

The Global Neurodegenerative Diseases Market 2015-2019 research report says reformulation of marketed drugs is boosting the growth of neurodegenerative diseases market during the period reviewed for forecasts in this research.

Complete report on neurodegenerative diseases market spread across 168 pages, providing 19 product profiles as well as analysis and profiles of 6 major companies supported with 92 exhibits is now available at .

According to this neurodegenerative diseases market report epilepsy represents a high level of unmet medical need in terms of the absence of any disease-modifying treatment. Currently, drugs used to treat the disorder are intended to treat seizures and fail to check the progression of the disease. These drugs cannot reverse the neuronal damage incurred by the patient. Drug delivery systems like transdermal patches, ER formulations and orally disintegrating tablets have increased drug efficacy because of the growing patient compliance and bioavailability of a drug. Reduction in side effects increases drug acceptance among patients and drives revenue growth. The dry syrup formulation of Aricept allows the adjustment of individual dose along with reducing the bulk of the drug, making it easier to swallow.

The key drivers of neurodegenerative diseases market discussed in this research include unmet medical needs, increase in patient population, promising drug pipeline and special provision for rare diseases. Market trends like reformulation of marketed drugs, emerging treatment options and increase in public awareness. Analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of neurodegenerative diseases. The market includes data from the sales of various drugs used in the treatment of: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy, Huntington's Disease and Amyotrophic Lateral Sclerosis.

Companies like Biogen Idec, Merck Serono, Novartis, Pfizer, Teva Pharmaceutical Industries, UCB, AB Science, Abbvie, Acorda Therapeutics, Actavis, Active Biotech, Adamas Pharmaceuticals, Akorn, Archer Pharmaceuticals, Astellas, Auspex Pharmaceuticals, Bayer, Boehringer Ingelheim, Covis, Desitin Arzneimittel, Eisai, Eli Lilly, Endo International, F. Hoffmann-La Roche, FORUM Pharmaceuticals, GlaxoSmithKline, Glenmark, H. Lundbeck, Ipsen, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Mitsubishi Tanabe, MorphoSys, Newron Pharmaceuticals, Omeros, Opexa, Orion, Otsuka Pharmaceutical, Oxford BioMedica, Palobiofarma, Prana Biotechnology, Raptor Pharmaceutical, Sanofi, Siena Biotech, SOM Biotech, STADA, Takeda Pharmaceutical, TauRx Pharmaceuticals, US WorldMeds, Valeant and Zinfandel Pharmaceuticals are mentioned in this report on neurodegenerative diseases market available for purchase at .

This research discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the neurodegenerative diseases market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of neurodegenerative diseases are discussed.

Another research titled Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders has a focus in biomarkers for neurodegenerative diseases and diagnostic applications in development. This report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers. In addition to covering background information, this report will highlight several technologies that have been developed for employing the use of biomarkers for neurodegenerative disease detection, analysis and therapeutic development. Including substantial background information, illustrated with graphics and figures, this report captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Three neurodegenerative disorders that are heavily focused on in this report include: Alzheimer's Disease/Mild Cognitive Impairment, Parkinson's Disease, and Amyotrophic Lateral Sclerosis. Part II of the report will include all three of these disorders, highlighting specifics including background, history, and development of the disease. Deeper into the chapters, the report will unfold biomarkers under investigation, genetic targets, and an analysis of multiple studies investigating these elements. One part of this research features a survey analysis exclusively done for this report. Qualifying participants worked with neurobiomarkers, neurodiagnostics, or both. With over 30 survey figures depicting the general R&D group working in this space, this section provides information including: research demographics, targets under investigation, challenges, advantages, and desired features of future diagnostic applications.

To add even more to the robustness of this report, the report puts together a generous amount of data compiling clinical trial information pipeline data related to Alzheimer's Disease, Parkinson's Disease and Amyotrophic Lateral Sclerosis. Order a copy of Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders report at .

Explore more reports on the pharmaceuticals market at .

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  




G+ / Google Plus:



Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441  

SOURCE ReportsnReports